Indaptus Therapeutics, Inc.
INDP
$6.52
-$0.55-7.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.42M | 7.52M | 8.11M | 8.57M | 8.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.34M | 16.00M | 15.37M | 15.37M | 16.48M |
| Operating Income | -16.34M | -16.00M | -15.37M | -15.37M | -16.48M |
| Income Before Tax | -16.96M | -15.75M | -15.02M | -14.89M | -15.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.96 | -15.75 | -15.02 | -14.89 | -15.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.96M | -15.75M | -15.02M | -14.89M | -15.75M |
| EBIT | -16.34M | -16.00M | -15.37M | -15.37M | -16.48M |
| EBITDA | -16.34M | -16.00M | -15.37M | -15.37M | -16.48M |
| EPS Basic | -37.72 | -41.78 | -45.41 | -48.16 | -52.20 |
| Normalized Basic EPS | -23.57 | -26.11 | -28.38 | -30.10 | -32.62 |
| EPS Diluted | -37.72 | -41.78 | -45.41 | -48.16 | -52.20 |
| Normalized Diluted EPS | -23.57 | -26.11 | -28.38 | -30.10 | -32.62 |
| Average Basic Shares Outstanding | 1.81M | 1.54M | 1.34M | 1.25M | 1.21M |
| Average Diluted Shares Outstanding | 1.81M | 1.54M | 1.34M | 1.25M | 1.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |